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Objectives: In European hospitals, budgetary pressure is driving centralized 
purchasing and increasing the importance of procurement in market access. 
Centralized purchasing is thought to lead to cost savings through stronger nego-
tiating power, economies of scale and reduced inventory. The objective of this 
study was to understand the procurement methods for disposable medical devices 
employed by European hospitals and their impact on market access. MethOds: 
A review of hospital purchasing practices was conducted in France, Germany and 
England, including published articles and government websites. Twelve 45-60 min-
ute telephone interviews were conducted with hospital decision makers (pur-
chasers, pharmacists and clinicians) in 2013. Results: Most disposable medical 
devices are evaluated at the facility level by committees made up of clinicians, 
procurement specialists, pharmacists and management. France and Germany 
require listing on the facility formulary and typically procure via tendering and 
group purchasing. England has a national procurement body but hospitals regu-
larly purchase products directly from the manufacturer. All three countries report 
that austerity measures are causing many facilities to limit the number of products 
per category. Product trials and clinician preference are seen as the main drivers 
of adoption however clinicians are under increasing pressure to justify costs. 
Hospital purchase decisions are increasingly likely to be based on non-product 
specific attributes such as total cost of purchasing including volume discounts, 
broad portfolio of products, and administrative costs. cOnclusiOns: In the cur-
rent environment, market access for disposable medical devices will require a 
strong economic argument in addition to evidence of superior quality. Although 
clinicians still drive the adoption of consumable medical devices, in the absence 
of a strong clinician preference, non-product specific attributes may determine 
market access. Manufacturers can support their economic messaging along cat-
egories of inventory reduction and a broad portfolio of products that allows for 
administrative efficiencies and reduced shipping costs.
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Objectives: The Portuguese National Health System (NHS) identified the 
need to easily access information that allowed identification of all medical 
devices (MDs) with their respective manufacturers, distributors, characteristics, 
and purposes. The objective of the creation of an information system is to col-
lect, store and analyze data of each MD and to provide NHS resources manage-
ment, health technology assessment (HTA), as well as data about the Portuguese 
market. MethOds: A system consisting of a database that is a repository, and 
an application system that stores the information was built. For the registry of 
information all MDs should disclose their respective instructions of use, labels 
and price. The concept of unique medical device and a process to assign a code to 
each device was designed, and tested by collecting data from NHS acquisitions. 
The prescription of medical devices is made by code, with all information online. 
A model for communication between the health regulatory agency and market 
operators was also devised, as well as rules and codes of procedure. Results: The 
creation of this system in 2011 allowed for the coding of 20% of all registered MDs 
(n= 838000) up to June 2014. This has allowed for the elimination or withdrawal of 
16% (n= 136000) of references, thus keeping the registries up to date. The coding 
permitted the comparison of devices and the management of total expenditure in 
MDs by hospitals of the NHS. cOnclusiOns: The system provides solid informa-
tion about available MDs in the market, their respective manufacturer, distributor 
and pricing to which they are sold to the NHS. The system is a support for decision 
makers, payers, and HTA processes. It facilitates the management and traceability 
of medical devices in hospitals and has impact on reimbursement, access and 
pricing varies by market.
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Objectives: Rapid increase of costs of reimbursement in Poland led to redesign of 
the drug pricing mechanisms. As a result a new law which brought revolutionary 
changes to the health care system was introduced in 2012. The aim of this work is 
to summarize the two years of new drug policy in Poland and to present mecha-
nisms that resulted in substantial savings in reimbursement costs. MethOds: 
Few savings-generating mechanisms were implemented in the new reimburse-
ment law: negotiations of prices, new method of calculation of reimbursement 
limit (resulting in higher co-payment) and also formal obstacles in obtaining pre-
scriptions for reimbursed products (some reimbursed drugs, i. e. antibiotics, due 
to formal issues are prescribed with 100% co-payment). The first and the third 
reason result in lower overall costs of reimbursed medicines, while the second 
reason influences the proportion of costs borne by the National Health Fund. We 
have analyzed data on prices of reimbursed drugs before 2012 and after imple-
mentation of the new law (currently the prices may change every two months). 
We have then compared the amount of sales of those drugs, costs of reimburse-
ment and patients’ co-payment. For some reference groups (i. e. oral aromatase 
inhibitors) we made in-depth analysis of pricing mechanisms. Results: In 2012 
total public expenditures amounted to 2.3 billion EUR, 83% of the planned budget, 
which gave 460 million EUR savings as compared to 2011. In 2013 the drug budget 
was executed in 87%, resulting in 430 million EUR savings. Saving were driven by 
price negotiations, but also by mechanisms of lowering the reimbursement limit, 
i. e. in case of oral aromatase inhibitors the reimbursement limit was lowered by 
half during 2012-2013. cOnclusiOns: The new reimbursement law resulted in 
substantial savings in costs of drugs. The success is however relative, as costs of 
drugs were partially shifted towards patients.
Objectives: The Moroccan government announced new public and hospital 
prices for 5308 drugs in April 2014. These price cuts came into force in June 2014. 
The study examines the price changes and analyzed the potential impact of the 
price cuts on pharmaceutical companies operating in the market. MethOds: 
Standard statistical methods were used to analyze government provided data in 
order to identify general trends within the pricing notification. Secondary sources 
were then examined to determine the general pricing rationale. Results: The 
price notification included 5308 drugs (note duplication occurs where a brand 
name has multiple formulations). Examining public prices: 390 of the drugs were 
newly listed on the list for public purchase, a further 2968 saw no price increase 
and two drugs saw modest price increases. Public price declines were seen for 
1948 drugs with the level of decline covering a range of 1635 percentages between 
0.006% and 78.6%. Average public price, excluding drugs with no decline, saw an 
average decline of 13.6% and median decline of 6.5%. All the 5308 drugs already 
had an existing hospital price, however 114 of these drugs saw no pricing change. 
Of the 5194 drugs which did see a price decline this varied across a range of 
2559 different percentages between 0.001% and 79.8%. The average hospital price 
decline, excluding drugs which saw no decline, was 9.3% and the median was 
5.8%. cOnclusiOns: The large range of pricing declines suggests that the prices 
were not indicative of a formulaic event such as currency fluctuation changes. 
This also means that there is a differential impact on pharma companies, with 
certain parts of their portfolio being more protected than others.
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Objectives: Unequal access due to delays or non-availability of medicines denies 
patients treatments they need and contributes to inequality across Europe. The 
EFPIA previously monitored access delays via the “Patients Waiting to Access 
Innovative Therapies (WAIT)” indicator, however; this has not been updated 
since 2011. Following the 2012 EC Transparency Directive 89/105/EEC mandating 
no more than 120 days of delay for national pricing and reimbursement deci-
sions, an updated evaluation is needed. MethOds: IMS MIDAS data was used to 
identify the first sale for all EMA-approved non-generic, non-biosimilar products 
since 2008 in 15 EU markets. The delay (from approval to first sale) was noted for 
each product and market and compared to the EFPIA Patients WAIT indicator for 
2008-2010. Annual average delays were calculated over the 2008-2013 period and 
for available products, an analysis of minimum and maximum delay performed 
for each market. Additional analyses were performed for trends within and across 
markets, and to identify progress and variations. Results: Improvements across 
the 2008-2012 period give cause for optimism in most European markets, as delays 
have fallen sharply in almost all markets, from an average of 524 days in 2008 to 
281 days in 2012, with only Greece showing no real improvement. However; abso-
lute availability of new medicines has varied greatly by market, with same-year 
availability of EMA-approved medicines declining to just 41% on average in 2013. 
Notable declines were seen in Greece, Spain, Romania and Portugal, suggesting 
that economic difficulties may lead some governments to refuse reimbursement, 
rather than simply delay decisions. cOnclusiOns: This updated access analysis 
shows that while delays are shortening, absolute access for patients is not always 
improving. Some new access rules such as “class C” drugs in Italy (access without 
funding), may send misleading signals, and underscore the need for monitoring 
of true access across Europe.
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Objectives: Market Access (MA) is key for medical devices given recent changes in 
regulation from one side, and pressures on costs from the other side. Nevertheless, 
there is scant evidence on how MA works in the medical device industry and 
whether it works effectively. The aims of the present study are to illustrate current 
gaps in MA for medical devices and to recommend future actions to make this 
function more effective. MethOds: We conducted a literature review aimed at 
gathering a clear picture of current state of the art on MA for medical devices and 
at highlighting major gaps vis-à-vis other industries (e.g. pharmaceuticals). Based 
upon the review’s findings, we carried out an e-survey to small, medium, and large 
device companies operating in the EU in order to understand: i) how MA is perceived 
and actually organised, ii) which are the main perceived obstacles to MA, iii) how 
companies invest in market access and at which stage of medical device develop-
ment, and iv) what the main challenges are to a more efficient market access pro-
cess. Results: The findings of the literature review and preliminary results of the 
e-survey are presented. cOnclusiOns: MA is an under-developed function in the 
medical device industry and in certain cases its role is not fully exploited. Although 
the pharmaceutical industry doesn’t represent a fully appropriate benchmark, MA 
for medical devices is even less developed when compared to its full potential. A 
different approach is needed to deal with new changes in the regulation and policy 
arenas aimed at synergistically encompassing knowledge, expertise and operating 
tools from public affairs, medical departments, pricing & reimbursement, health 
economics and marketing.
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studies or participate in joint projects, whereas 69% plan to conduct HSR studies in 
the near future. All these numbers increased since the last surveys. cOnclusiOns: 
The results of the survey clearly pointed out the high and still increasing importance 
of HSR and real-life studies also in the health care industry. Although a considerable 
amount of uncertainty concerning the specific methodological requirements remain 
it is widely accepted that the quality of data and analyses is crucial for acceptance 
by payers. As HSR projects require considerable human and financial resources alli-
ances and joint projects between industry, academia and payer are aspired.
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Objectives: In France, drugs and medical devices costs concern an important part 
of health care expenditure. Several reforms have been put in place over the past 
years in order to limit these expenditures, in particular price cutting policy. Cost-
effectiveness assessment was integrated in France in the market access scheme 
of health products by the Social Security Financing Act for 2012 and is required 
since October 3rd 2013. This new mission was assigned to the Health Economics 
and Public Health Committee (CEESP) of the French National Authority for Health 
(HAS) and is become compulsory for innovative health products and are likely to 
have a significant impact on the health insurance expenditures. The objectives of 
this work were to see how the cost-effectiveness assessment has been integrated in 
France and to discuss the impact of this assessment on the health products market 
access. MethOds: The work consists in analyzing the process of the economic 
evaluation achieved by the HAS since October 3rd 2013. Results: Economic evalu-
ation is a new step in the market access scheme. In order to respect the legislated 
timeframe of 90 days, it is simultaneously conducted with the medical assessment 
by the Transparency Commission of the HAS. For each health products, an efficiency 
opinion is delivered by the CEESP. It presents the methodological conformity accord-
ing to HAS guidelines and a conclusion about the efficiency, on the basis of the 
Incremental Cost-Effectiveness Ratio (ICER). Currently, 15 dossiers were eligible for 
cost-effectiveness assessment. First assessments permit to confirm that the pro-
cedure is operational. The average processing time was 94,8 days. cOnclusiOns: 
In France without efficiency threshold value, the CEESP can’t conclude absolutely 
on the efficiency of health product. We don’t know how the ICER will be considered 
by the French Healthcare Products pricing Committee (CEPS) at the time of pricing 
negotiation with the pharmaceutical industry.
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Objectives: In France, cost-effectiveness assessment is required since October 3rd 
2013 for innovative health products and are likely to have a significant impact on 
the health insurance expenditures. The objective of this work is to report first cost-
effectiveness assessments, achieved by the Health Economics and Public Health 
Committee (CEESP) of the French National Authority for Health (HAS). MethOds: 
The investigation consists in analyzing medico-economic dossiers submitted at 
the CEESP between October 2013 and October 2014. This analysis is based on the 
opinion delivered by the CEESP, the methodology used in the model and the pro-
cess of the assessment achieved by the HAS. Results: At the time of writing the 
abstract, 15 dossiers were eligible for cost-effectiveness assessment. All dossiers 
were based on cost-utility models. Two dossiers presented a negative opinion due 
to the methodological conformity according to HAS guidelines. For dossiers with 
a positive opinion, the Incremental Cost-Effectiveness Ratio (ICER) were between 
5 866€ /QALY (for a subgroup analysis) and 194 531 € /QALY. Main methodological 
reserves made by the CEESP concerned comparators, time horizon, robustness of 
clinical data, utility measures. The average processing time was 94,8 days. For the 
moment, no price has been published in the Official Journal. cOnclusiOns: The 
first assessments permit to confirm that the procedure is operational. In light of 
these first assessments, an update of the HAS methodological guidelines should 
be done. In France, without efficiency threshold value, the CEESP can’t conclude 
absolutely on the efficiency of health products. Thus, we don’t know what will be 
the place of the ICER in the pricing negotiation between the pharmaceutical industry 
and the French Healthcare Products pricing Committee (CEPS).
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Objectives: The objective of this research is to provide an overview of the regula-
tory process of medical devices in China. Potential challenges related to medical 
device registration and major policy changes are highlighted especially since the 
restructuring of the China FDA in March 2013. The results of this research are aimed 
at informing regulatory bodies, health policy decision makers, national and interna-
tional Health Technology Assessment networks, as well as medical devices manu-
facturers. MethOds: A systematic review was conducted from 2009-2013 to identify 
the challenges and opportunities in the Chinese medical device regulatory process 
searching the PubMed, Science Direct, Scopus databases and Zhongguozhiwang. 
The PRISMA guidelines were applied for the search. In addition, an analysis of 
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Objectives: Therapeutic Positioning Reports (TPRs) were introduced to the 
Spanish P&R process in May 2013. TPRs evaluate comparative efficacy and safety 
and introduce usage and monitoring criteria for new drugs and existing drugs seek-
ing reimbursement. The procedure was set-up by the Spanish Medicines Agency 
(AEMPS) and the Ministry of Health with the aim to accelerate the P&R process 
and to generate a single, national relative effectiveness report avoiding additional 
regional evaluations, contributing to reducing the long-delays in market access 
timelines experienced in the last few years. The objective of this ongoing work 
is to describe and analyze both the metrics of the process and the contents and 
results of TPRs. MethOds: Descriptive study based on public information available 
from the European and Spanish Medicines Agencies (May 2013-ongoing). Results: 
From June 2013 to May 2014 the Therapeutic Positioning Coordinating Group 
(TPCG) has officially launched 60 TPR plus 7 use protocols (UP) at the request of 
the Interministerial Price Council (IMPC). 75% of TPR involve new chemical enti-
ties (82% of those with a positive opinion from the CHMP between May 2013-April 
2014) and assess a single entity (48% specialty care) indicated, mainly, for patients 
with neoplastic (28%) and endocrine (18%) diseases. All UP affect targeted therapies 
with approval between Jan2010-Dec2012. Since its establishment in May 2013, the 
TPCG has released 26 TPR (57% of those expected according to the pre-established 
procedure -3 months working time) with a median release time of 7,1 months. Only 
1 has been published. The rest await for P&R decisions. Other 5 pilots have been 
published in parallel. In total 5 TPR recommend to further restrict the European 
label. cOnclusiOns: TPR are not being released at the expected rate. Follow up is 
necessary to predict its impact in P&R and market access in regions across Spain.
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Objectives: Medical devices constitute a set of important health technologies for 
the care of patients. While there are similarities between some reimbursement 
systems, each market has its own unique characteristics. This article focuses on 
the reimbursement procedures for medical devices in the DACH countries (Austria, 
Germany, Switzerland), and aims at finding commonalities in payer requirements 
and reimbursement pathways. MethOds: Reimbursement application pathways 
for inpatient and outpatient medical devices were evaluated for Austria, Germany 
and Switzerland. The key items being analysed for similarities and differences in 
each setting were transparency, clinical and health economic evidence require-
ments, submission timelines and the length of the whole reimbursement appli-
cation process. Results: In the inpatient setting, the evidence requirements for 
clinical data are different between the analysed countries: The lowest clinical evi-
dence requirements are seen in Germany, while the highest are given in Switzerland 
(in some scenarios). In terms of health economics the requirements are medium 
to low. A medium rating was given for Austria and Switzerland (in some scenarios) 
as a health economic analysis is required (e.g. cost comparison), and a low rat-
ing was applied to Germany as limited economic information (cost assessment/
comparison) needs to be submitted. The length of the application process is well 
defined in Austria and Germany and vague in Switzerland. In the outpatient setting 
the requirements for clinical and health economic data are significantly increas-
ing. Clinical requirements are getting close to pharmaceutical methods whereas 
health economic evidence is requested in all DACH countries. The length of the 
reimbursement process is not clearly defined in all three countries. cOnclusiOns: 
Despite varying reimbursement processes within the DACH region, there are some 
important similarities between the evidence requirements which may help manu-
facturers to guide market access and reimbursement strategy decisions in order 
to drive successful submissions and applications of innovative medical devices.
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Objectives: The necessity for manufacturer of pharmaceuticals and medical 
devices seem to deal with health services research (HSR). Health care reform acts 
and revisions of HTA method guidance documents in many European countries 
continue to point out the importance of real-life consequences. The objective of the 
study was to evaluate the self-reported importance and the own activities of phar-
maceutical companies in Germany concerning health services research. MethOds: 
Between December 2013 and February 2014 an online survey among members of 
the German Pharmaceutical Industry Association (BPI) was accomplished. Similar 
surveys were conducted in 2009 and 2011. Results: 59% of 109 addressed com-
panies took part in the survey. The participants were representative for Germany 
concerning research-orientation, size and type of products. For 88% of the participat-
ing companies HSR is of importance. This high rate remained constant compared 
to the last surveys. For most of the companies HRS yields valuable contributions 
for the negotiations with payers (96%), in the AMNOG evaluation process (89%) and 
for optimization of placement of marketed products (94%). 50% of the companies 
conducted HSR studies over the last years, respectively are currently conducting HSR 
